| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
|
Hogan, Andrew E.
|
|
2011
|
140 |
2 |
p. 196-207
12 p.
|
artikel
|
| 2 |
Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer
|
Motohashi, Shinichiro
|
|
2011
|
140 |
2 |
p. 167-176
10 p.
|
artikel
|
| 3 |
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
|
Metelitsa, Leonid S.
|
|
2011
|
140 |
2 |
p. 119-129
11 p.
|
artikel
|
| 4 |
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant
|
Padte, Neal N.
|
|
2011
|
140 |
2 |
p. 142-151
10 p.
|
artikel
|
| 5 |
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
|
Schneiders, Famke L.
|
|
2011
|
140 |
2 |
p. 130-141
12 p.
|
artikel
|
| 6 |
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects
|
Exley, Mark A.
|
|
2011
|
140 |
2 |
p. 184-195
12 p.
|
artikel
|
| 7 |
Editorial Board
|
|
|
2011
|
140 |
2 |
p. IFC-
1 p.
|
artikel
|
| 8 |
Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges
|
Dhodapkar, Madhav V.
|
|
2011
|
140 |
2 |
p. 160-166
7 p.
|
artikel
|
| 9 |
NKT-cell-based immunotherapies in clinical trials
|
Exley, Mark A.
|
|
2011
|
140 |
2 |
p. 117-118
2 p.
|
artikel
|
| 10 |
On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies
|
Dellabona, Paolo
|
|
2011
|
140 |
2 |
p. 152-159
8 p.
|
artikel
|
| 11 |
Targeting iNKT cells for the treatment of sickle cell disease
|
Field, Joshua J.
|
|
2011
|
140 |
2 |
p. 177-183
7 p.
|
artikel
|
Tijdschrift beschrijving